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Abstract
Background: There is a lack of high-quality meta-analyses and network meta-analyses of immunosuppressive drugs
for lupus nephritis. Our objective was to assess the comparative benefits and harms of immunosuppressive drugs
and corticosteroids in lupus nephritis.
Methods: We conducted a systematic review and network meta-analysis (NMA) of trials of immunosuppressive
drugs and corticosteroids in patients with lupus nephritis. We calculated odds ratios (OR) and 95 % credible
intervals (CrI).
Results: Sixty-five studies that met inclusion and exclusion criteria; data were analyzed for renal remission/response
(37 trials; 2697 patients), renal relapse/flare (13 studies; 1108 patients), amenorrhea/ovarian failure (eight trials; 839
patients) and cytopenia (16 trials; 2257 patients). Cyclophosphamide [CYC] low dose (LD) and CYC high-dose (HD)
were less likely than mycophenolate mofetil [MMF] and azathioprine [AZA], CYC LD, CYC HD and plasmapharesis
less likely than cyclosporine [CSA] to achieve renal remission/response. Tacrolimus [TAC] was more likely than CYC
LD to achieve renal remission/response. MMF and CYC were associated with a lower odds of renal relapse/flare
compared to PRED and MMF was associated with a lower rate of renal relapse/flare than AZA. CYC was more likely
than MMF and PRED to be associated with amenorrhea/ovarian failure. Compared to MMF, CYC, AZA, CYC LD, and
CYC HD were associated with a higher risk of cytopenia.
Conclusions: In this systematic review and NMA, we found important differences between immunosuppressives
used for the treatment of lupus nephritis. Patients and physicians can use this information for detailed informed
consent in a patient-centered approach. Study limitations of between-study clinical heterogeneity and small sample
size with type II error must be considered when interpreting these findings.
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Background
Lupus is a chronic autoimmune disease that fre-
quently involves the kidney. Lupus nephritis can lead
to kidney failure, dialysis, and even premature death
if not treated appropriately. Lupus primarily affects
young women and is more common and more severe
in racial/ethnic minorities, who experience worse out-
comes [1–5].
Comparative effectiveness research (CER) of drugs
used to treat lupus nephritis is an imperative [6]. Pa-
tients, facing difficult decisions related to their treatment
options, such as those related to life- and/or organ-
threatening clinical situations (active lupus nephritis, for
example) need information about possible harms and
benefits of available treatment options in a format that
provides comparisons of multiple treatment options.
The 2012 American College of Rheumatology (ACR)
lupus nephritis treatment guidelines [7] and the
Cochrane systematic review of interventions for lupus
nephritis [8] assessed literature up to 2010 and 2012, re-
spectively. However, indirect comparisons were not per-
formed in either. Few lupus nephritis treatments have
been compared directly in clinical trials. This leaves a
large knowledge gap. Clinicians and patients have to
choose between various immunosuppressive drugs in the
absence of such knowledge. Therefore, we need evidence
synthesis using valid methods to incorporate indirect
and direct comparisons of efficacy/harms of these
treatments.
A state-of-the-art network meta-analysis (NMA), with
updated information, is a necessary precursor to the de-
velopment of a clinical decision-making tool for physician
and their patients with lupus nephritis. This information
can be very helpful to patients during the treatment
decision-making process for new disease, disease flare or
refractory disease. It is not surprising that for a rare condi-
tion such as lupus with roughly 161,000 patients in the
USA [9], most multicenter trials have <500 patients (often
50–200 patients). This makes many trials underpowered
for assessing treatment-related differences in disease
outcomes.
One useful approach is the use of composite out-
comes, which have been widely used to address import-
ant clinical questions in obstetrics, cardiology, and other
disciplines [10–12]. Assessments of treatment options
using composite outcomes can help answer important
question in a timely fashion without requiring studies
with large sample sizes. This study aimed to perform a
systematic review and NMA to compare benefits and
harms of immunosuppressive drugs compared to each
other and to corticosteroids focusing on four composite
benefit/harm outcomes: (1) renal remission/response;
(2) renal relapse/flare; (3) ovarian failure/amenorrhea;
and (4) bone marrow toxicity.
Methods
We used rigorous methods for the systematic review and
NMA based on the Agency for Healthcare Research and
Quality (AHRQ) recommendations [13], the Cochrane
handbook [14], and the PRISMA guidelines. The
Institutional Review Board at the University of Alabama
at Birmingham (UAB) approved the study. The need for
informed consent was waived for this systematic review,
since no human subjects were involved. The study proto-
col was registered in PROSPERO, CRD42016032965
(http://www.crd.york.ac.uk/PROSPERO/).
Methods for systematic review: study eligibility criteria,
outcomes and data abstraction
This systematic review included randomized controlled
trials (RCTs) or controlled clinical trials (CCTs) of im-
munosuppressive drugs or corticosteroids for lupus
nephritis, published in English that reported any safety
or efficacy outcome. Included medications were: cortico-
steroids [PRED]; cyclophosphamide [CYC]; mycopheno-
late mofetil [MMF]; azathioprine [AZA]; cyclosporine
[CSA]; tacrolimus [TAC]; or rituximab [RTX], Belimumab
studies could not be included in this systematic review
since these studies included patients with lupus, and only
a small proportion had active lupus nephritis. A Cochrane
systematic review of belimumab for lupus in underway
[15]. There were no restrictions with regards to the medi-
cation dose or the duration of medication use.
Experienced librarians (JJ and TR) updated two system-
atic reviews [7, 8] from their search end dates (August
2010 and April 2012, respectively) to September 2013
using the PubMed database. The search used the follow-
ing terms: (Lupus[text word] OR "Lupus Vulgaris"[MeSH]
OR "Lupus Erythematosus, Cutaneous"[MeSH] OR
"Lupus Erythematosus, Systemic"[Mesh]) AND ("Kidney
Diseases"[MeSH] OR nephropath*[text word] OR Trans-
plants[MeSH] OR Transplantation[MesH] OR transplan-
tation[subheading] OR transplant*[text word] OR
"Kidney"[Mesh] OR Kidney*[text word] OR Renal*[text
word] OR "End Stage Renal Disease"[text word] OR
ESRD[text word] OR Glomerulonephr*[text word] OR
"GN"[text word] OR "crescentic GN"[text word]) NOT
("animals"[MeSH] NOT "humans"[MeSH]).
Raw data abstracted for the ACR lupus nephritis
guidelines systematic review [7] were obtained (cour-
tesy Dr. Jennifer Grossman (JG), see acknowledgment
section), or were abstracted from the Revman tables
of the Cochrane Systematic Review [8]. A librarian
(CH) also performed a search for all lupus trials for
harms (for conditions other than lupus nephritis) in
PubMed and SCOPUS from inception to February
2014, based on an a priori assumption that treatment-
related harms may not depend on whether kidney is
involved or not. Examination of data from this search
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revealed little additive data for harms, but added clin-
ical heterogeneity related to differences in patient
population. Therefore, after careful consideration of
pros and cons, we decided not to use these data in
analyses.
The PICO (patient, intervention, comparator, out-
come) for our systematic review and NMA were defined
as follows:
P: Adults 18 years or older, meeting the 1987
American College of Rheumatology Classification
criteria for systemic lupus erythematosus (SLE) [16],
who have lupus nephritis.
I: Immunosuppressant drug alone or in combination
with other immunosuppressant drugs or biologics
(such as rituximab) or corticosteroids. Medication
doses were categorized as low, standard or high dose/
duration (LD, SD and HD).
C: Placebo or another immunosuppressive with/
without biologic.
O: Benefit and harm outcomes (renal remission/
response, renal relapse/flare, fertility, bone marrow
suppression), defined as follows.
Benefits were assessed by two composite outcomes (for
detailed definitions of components, see Additional file 1):
(1) renal remission/response (indicating success of
therapy): included complete renal remission, [17] partial
renal remission [18, 19] and renal response; (2) renal
relapse/flare (indicating failure of therapy): included renal
relapse [20] and renal flare (Additional file 1). Harms were
assessed by two composite outcomes: (1) ovarian failure/
amenorrhea: included ovarian failure and amenorrhea;
and (2) bone marrow toxicity: cytopenia including
leucopenia.
Two trained abstractors (AO, AB) independently
reviewed abstracts and titles, abstracted data in duplicate
directly into Microsoft excel sheets and assessed the risk
of bias according to the Cochrane risk of bias tool [21].
We examined the following domains as low or high risk
of bias or unclear risk (lack of information or uncer-
tainty about potential for bias): randomization sequence
generation, allocation sequence concealment, blinding of
participants, personnel and outcome assessors, incom-
plete outcome data (primary outcome data reporting,
dropout rates and reasons for withdrawal, appropriate
imputation of missing data, an overall completion rate
≥80 %), and selective outcome reporting and other po-
tential threats to validity (considering external validity,
e.g., relevant use of co-interventions, bias due to funding
source). An adjudicator (JS) resolved any disagreements
not resolved by consensus. An expert rheumatologist
(JS) and an expert in lupus (JG) examined for similarity
of studies prior to performing evidence synthesis by the
examination of similarity of study population and
interventions.
We designated doses as follows: (1) CYC: standard-
dose/duration , SD: 0.5–1.0 gm/m2 intravenously (IV) q
month for 6–12 months or 2–2.5 mg/kg orally (PO) daily
× 3–6 months; high-dose/duration, HD: dose higher or
duration longer than SD; low-dose/duration, LD: lower
dose or duration shorter than SD, including the EURO-
lupus dose, 500 mg IV q14 days × 6 doses (mean
3 g); (2) AZA: SD, 1–3 mg/kg po daily; HD, >3 mg/kg po
daily; (3) LEF: 1 mg/kg po qd × 3 days then 30 mg
Fig. 1 PRISMA study flow chart for study selection. Legend: none
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po qd x 6 months; and (4) PRED: SD, prednisone/
methylprednisolone 1 gm/m2 IV q month × 6 months
or prednisone 60 mg po qd 1–3 months then tapered
over 3–12 months as tolerated; HD, prednisone/meth-
ylprednisolone 1gm/m2 qd IV × 3, then one dose q
month for 1 year or prednisone 1 mg/kg daily for 4–
8 weeks (or unspecified period). When dose is not
specified, medication dose is the standard dose.
Bayesian network meta-analysis (NMA)
We used Bayesian mixed treatment comparison (MTC)
meta-analyses [22–24] to assess the comparative
Fig. 2 Network diagrams for composite study outcomes in lupus nephritis, renal remission or renal response (a), renal relapse or renal flare (b),
fertility issues (c), and bone marrow toxicity (d). Legend: Each node shows the treatment compared along with the number of RCTs that provide
evidence. The size of each node is proportional to the sample size. a shows only the direct evidence, while b–d show both direct and indirect
evidence. Direct evidence is indicated by lines indicating the number of RCTs providing the evidence and indirect by lines without this
information. This was done since there were several direct comparator studies available for a, and addition of connections based on indirect
evidence to a would make the network diagram very complex and difficult to visualize and understand
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Table 1 Risk of bias of included studies according to the Cochrane Risk of Bias toola
















Austin 2009 Low risk Low risk High risk High risk Unclear risk Unclear risk Unclear risk
Carette 1983 Unclear risk Unclear risk High risk High risk Low risk High risk Low risk
Steinberg 1991 Low risk Low risk Low risk Low risk Low risk Unclear risk Unclear risk
Donadio 1976 Unclear risk Unclear risk High risk High risk Low risk Unclear risk Low risk
Pohl 1991 Unclear risk Unclear risk High risk High risk Unclear risk Unclear risk Unclear risk
Wang 2007 Unclear risk Unclear risk High risk High risk High risk Unclear risk Unclear risk
Isenberg; An analysis
of ALMS study
2010 Low risk Low risk Low risk Unclear risk Low risk Low risk Unclear risk
Appel (ALMS study) 2009 Low risk Low risk Low risk Unclear risk Low risk Low risk Unclear risk
Austin 1986 Low risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Balletta 1992 Unclear risk Unclear risk Low risk Low risk Low risk Unclear risk Low risk
Bao 2008 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Barron 1982 High risk High risk Low risk Low risk High risk High risk Low risk
Boumpas 1992 Unclear risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Cade 1973 High risk Unclear risk Low risk Low risk Unclear risk Unclear risk Unclear risk
Chan 2000 Low risk Unclear risk Low risk Low risk Low risk Low risk Unclear risk
Chen 2011 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Clark 1981 Unclear risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Clark 1984 Unclear risk Unclear risk Low risk Low risk Unclear risk Unclear risk Unclear risk
Contreras 2002 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
CYCLOFA-LUNE
Study
2010 Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Derksen 1988 Low risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Donadio 1974 Low risk Unclear risk Low risk Low risk Unclear risk High risk Low risk
Donadio 1978 Low risk Unclear risk Low risk Low risk Unclear risk Unclear risk Unclear risk
Doria 1994 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Dyadyk 2001 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
El-Shafey 2010 Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Fu 1998 Low risk Low risk Low risk Low risk Low risk High risk Low risk
Ginzler 2005 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Gourley 1996 Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Grootscholten
(Dutch Lupus study)
2006 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Hahn 1975 Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Hong 2007 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Houssiau 2002 Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Lewis 1992 Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Li 2009a Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Li 2009b Unclear risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Lui 1997 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
LUNAR Study 2012 Low risk Unclear risk Low risk Low risk Low risk Low risk Unclear risk
MAINTAIN Nephritis
Study
2010 Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Mitwalli 2011 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
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effectiveness of one immunosuppressive drug vs. another
and immunosuppressive drugs vs. corticosteroids. Bayes-
ian MTC meta-analysis using a binomial likelihood model
was conducted using WinBUGS software (MRC Biostatis-
tics Unit, Cambridge, UK) which allows inclusion of data
from multi-arm trials [25, 26] We conduced random-
effects NMA and assessed model fit and the choice of
model (random vs. fixed effects) based on the assessment
of the deviance information criterion (DIC) and the com-
parison of residual deviance to the number of uncon-
strained data points [25, 27].
We assigned vague priors, such as N(0, 1002) for
basic parameters throughout [25] and informative
priors for the variance parameter based on Turner et
al. [28]. We evaluated the model diagnostics including
trace plots and the Brooks-Gelman-Rubin statistic to
ensure model convergence [25, 29]. We fit three
chains in WinBUGS for each analysis, with 40,000 it-
erations, and a burn-in of 40,000 iterations [29, 30]
Both MTC and traditional meta-analysis require
studies to be sufficiently similar in order to pool their
results. We investigated heterogeneity, where war-
ranted, with subgroup analyses and meta-regressions
[26, 31]. We examined consistency-inconsistency plots
for evidence of inconsistency, and chose the appropri-
ate model for our analyses. We obtained point esti-
mates using odds ratios (OR) and 95 % credible
intervals (CrI) using Markov Chain Monte Carlo
(MCMC) methods. Transformation of the OR to
relative risk (RR) and risk difference was done to
allow ease for interpretation for clinicians and pa-
tients. The quality of evidence was assessed as recom-
mended in a recent study [32].
Sensitivity analysis was performed by limiting analyses to
partial/complete remission rather than combining this with
renal response for the composite renal remission/response.
We constructed staircase diagrams, another pictorial way to
see comparisons of various treatments to each other.
Table 1 Risk of bias of included studies according to the Cochrane Risk of Bias toola (Continued)
Mok 2009 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Moroni 2004 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Mulic-Basic 2008 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
My-Lupus Study 2010 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Ong 2005 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Sabry 2009 High risk High risk Low risk Low risk Low risk Low risk Low risk
Sesso 1994 Unclear risk Unclear risk High risk Low risk Low risk Unclear risk Low risk
Steinberg 1971 Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk
Sundel/Sandel 2008 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Wallace 1998 Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Yee 2004 Low risk Unclear risk Low risk Low risk Low risk High risk Low risk
Li 2012 Unclear risk Unclear risk High risk High risk High risk Unclear risk Low risk
Yap 2012 Unclear risk Unclear risk High risk High risk High risk Unclear risk Unclear risk
Stoenoiu 2012 Unclear risk Unclear risk Unclear risk Unclear risk High risk Unclear risk Unclear risk













2013 Low risk Low risk Low risk Unclear risk Low risk Low risk Unclear risk
PetrI 2010 Low risk Unclear High risk High risk Low risk Unclear risk Low risk
Zeher 2011 Low risk Low risk High risk High risk High risk Unclear risk High risk
Dooley 2011 Unclear risk Unclear risk Unclear risk Unclear risk High risk Unclear risk High risk
Radhakrishnan 2010 was a pooled analyses of two studies, and Mok 2001, Hu 2002, and Wang 2008 [33–36] were observational studies used in the Cochrane
Review; therefore, risk of bias could not be assessed for these studies
aHiggins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org/. In: Higgins JP, Green S, eds 2011
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Rankograms were constructed to model the probabilities of




Sixty-five studies met inclusion and exclusion criteria that
included CYC, MMF, AZA, calcineurin inhibitors
(cyclosporine, tacrolimus), rituximab, corticosteroids,
plasmapharesis, or leflunomide (Fig. 1). The Additional
file 2 shows the search strategy. An additional file
shows the PRISMA checklist (see Additional file 3).
Network diagrams for all outcomes are shown in Fig. 2.
Most studies (88 %) compared induction or induction
and maintenance regimens. An additional file shows this
in more detail (see Additional file 4). The study sample
size ranged from 10 to 370. Of these, 32 % of the studies
were conducted in the USA and 43 % were multicenter.
A detailed risk of bias using the Cochrane risk of bias
tool is provided in Table 1. Randomization was low-risk
in 56 %, unclear in 39 % and high-risk in 5 % (Table 1).
Most trials were low-risk for blinding of assessor (59 %),
blinding of participant (54 %), intention to treat (57 %).
On the other hand, only 38 % of trials were low-risk for
allocation concealment and it was unclear in 59 %.
Although some clinical heterogeneity was detected
between trials overall, we did not notice any clinically
significant systematic differences in patient populations
or disease stages between various medications.
Treatment efficacy: complete/partial renal
remission/response
Thirty-seven trials with 2697 patients provided data for
the composite outcome, partial or complete renal remis-
sion or renal response (two trials were excluded since
they had variable duration of treatments based on re-
sponse to initial treatment, also associated with high
standard errors and wide CrI, leading to problems with
convergence of the model when included). There were
34 two-arm and three three-arm trials. Table 2 shows
only the significant odds ratios, relative risk and risk dif-
ferences only, and an additional file shows all compari-
sons in more detail (see Additional file 5). CYC, MMF,
CSA, and TAC were superior to corticosteroids alone in
achieving renal remission/response (Table 2). CYC low
dose (LD) was less likely than MMF, TAC, CSA, and
CYC and CYC HD less likely than MMF and CSA to
achieve renal remission/response. CSA was more likely
than plasmapharesis and azathioprine to achieve renal
remission/response (Table 2). The quality of evidence
Table 2 Significant differencesa between treatments of lupus nephritis for a composite end-point of renal remission or renal
response (includes partial remission, complete remission and renal response)
Treatment Reference Odds ratio (95 % CrI) Relative risk (95 % CrI) Risk difference % (95 % Crl)
CYC PRED 2.35 (1.28, 4.23) 1.60 (1.60, 2.24) 0.21 (0.06, 0.34)
MMF 3.26 (1.57, 6.72) 1.82 (1.82, 2.60) 0.28 (0.11, 0.44)
TAC 2.51 (1.11, 5.76) 1.64 (1.64, 2.44) 0.22 (0.03, 0.41)
CSA 5.69 (2.02, 17.61) 2.15 (2.15, 3.18) 0.40 (0.17, 0.58)
CYC LD CYC 0.32 (0.10, 0.89) 0.51 (0.51, 0.95) −0.26 (−0.45, −0.03)
CYC LD MMF 0.23 (0.08, 0.61) 0.45 (0.45, 0.81) −0.34 (−0.53, −0.12)
CYC HD 0.40 (0.20, 0.74) 0.65 (0.65, 0.89) −0.22 (−0.38, −0.07)
CSA AZA 3.20 (1.04, 10.19) 1.53 (1.53, 2.39) 0.26 (0.01, 0.47)
CYC LD TAC 0.30 (0.09, 0.91) 0.50 (0.50, 0.95) −0.28 (−0.50, −0.02)
PLASMA CSA 0.19 (0.04, 0.92) 0.49 (0.49, 0.97) −0.38 (−0.66, −0.02)
CYC LD 0.13 (0.03, 0.52) 0.38 (0.38, 0.76) −0.45 (−0.69, −0.15)
CYC HD 0.23 (0.06, 0.72) 0.55 (0.55, 0.87) −0.33 (−0.57, −0.08)
CYC HD 0.23 (0.06, 0.72) 0.55 (0.55, 0.87) −0.33 (−0.57, −0.08)
Random-effects model Residual deviance 82.2 vs. 77 data points
Deviance information criteria 389.332
Fixed-effects model Residual Deviance 88.8 vs. 77 data points
Deviance information criteria 390.488
Based on 37 RCTs with 2697 patients: 35 two-arm trials and three three-arm trials
aFor all comparisons of treatments of lupus nephritis for renal remission/response please see Appendix 5
For absolute rates for events used for calculation of risk difference, please see Appendix 6
OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, CYC cyclophosphamide, MMFmycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide,
PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab, HD high dose, LD low dose, when not specified, it indicates standard dose
Significant odds ratios are in italics
The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients
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was rated as moderate (downgraded for imprecision).
Absolute event rates ranged from 28 to 75 % and are
shown in more detail in an additional file (see Add-
itional file 6).
Treatment failure: renal relapse/renal flare
Thirteen studies with 1,108 patients provided data; 11
were two-arm and two were three-arm studies. MMF
and CYC were associated with a lower rate of renal re-
lapse/flare compared to PRED and MMF was associated
with a lower rate of renal relapse/flare than AZA
(Table 3). The quality of evidence was rated as moderate
(downgraded for imprecision). The event rates ranged
from 14 to 49 % and are shown in more detail in an
additional file (see Additional file 6).
Amenorrhea/ovarian failure
Eight RCTs with 839 patients provided data; seven were
two-arm and one trial was a three-arm trial. CYC was
more likely than MMF and PRED to be associated with
amenorrhea/ovarian failure (Table 4). CYC LD was asso-
ciated with higher risk of amenorrhea/ovarian failure
than MMF. The quality of evidence was rated as moder-
ate (downgraded for imprecision). Absolute event rates
ranged from 8 to 61 % and are shown in more detail in
an additional file (see Additional file 6).
Bone marrow toxicity: cytopenia (including leucopenia)
Sixteen trials provided data on 2257 patients: 15 were
two-arm and one was a three-arm trial. Compared to
MMF, several immunosuppressive drugs were associated
with a higher risk of cytopenia: CYC, AZA, CYC LD,
Table 3 Comparison of all lupus nephritis treatments for a composite of renal relapse or renal flare
Treatment Reference Odds ratio (95 % CrI) Relative risk (95 % CrI) Risk difference % (95 % Crl)
AZA PRED 0.33 (0.08, 1.23) 0.50 (0.17, 1.12) −0.24 (−0.47, 0.05)
MMF 0.17 (0.04, 0.67) 0.29 (0.09, 0.78) −0.34 (−0.53, −0.09)
CYC 0.18 (0.05, 0.58) 0.31 (0.11, 0.71) −0.33 (−0.51, −0.12)
CSA 0.24 (0.03, 1.60) 0.39 (0.07, 1.26) −0.29 (−0.52, 0.11)
CYC + AZA 0.32 (0.05, 1.67) 0.48 (0.10, 1.29) −0.25 (−0.50, 0.12)
MMF-AZA 0.41 (0.03, 5.46) 0.58 (0.07, 1.83) −0.20 (−0.51, 0.36)
MMF AZA 0.51 (0.32, 0.87) 0.59 (0.38, 0.90) −0.10 (−0.20, −0.02)
CYC 0.55 (0.24, 1.26) 0.62 (0.32, 1.21) −0.09 (−0.26 0.03)
CSA 0.74 (0.18, 2.95) 0.80 (0.23, 2.01) −0.04 (−0.23, 0.23)
CYC + AZA 0.95 (0.27, 3.09) 0.96 (0.34, 2.11) −0.01 (−0.19, 0.24)
MMF-AZA 1.23 (0.14, 12.15) 1.16 (0.19, 3.76) 0.04 (−0.25, 0.53)
CYC MMF 1.06 (0.44, 2.58) 1.05 (0.51, 2.29) 0.01 (−0.13, 0.12)
CSA 1.43 (0.32, 6.17) 1.33 (0.36, 3.81) 0.04 (−0.12, 0.35)
CYC + AZA 1.84 (0.51, 6.00) 1.62 (0.56, 3.85) 0.08 (−0.07, 0.35)
MMF-AZA 2.39 (0.27, 23.30) 1.94 (0.31, 6.94) 0.13 (−0.12, 0.63)
CSA CYC 1.35 (0.27, 6.52) 1.27 (0.31, 3.86) 0.04 (−0.14, 0.37)
CYC + AZA 1.72 (0.44, 6.37) 1.53 (0.49, 3.83) 0.08 (−0.09, 0.3)
MMF-AZA 2.24 (0.24, 23.15) 1.85 (0.28, 6.46) 0.13 (−0.13, 0.63)
CYC + AZA CSA 1.27 (0.20, 8.09) 1.20 (0.30, 5.35) 0.03 (−0.29, 0.35)
MMF-AZA 1.67 (0.13, 25.89) 1.43 (0.19, 8.68) 0.08 (−0.31, 0.62)
MMF-AZA CYC + AZA 1.30 (0.22, 9.13) 1.20 (0.28, 3.68) 0.04 (−0.01, 0.46)
Random-effects model Residual deviance 32.06 vs. 28 data points
Deviance information criteria 146.869
Fixed-effects model Residual deviance 34.31 vs. 28 data points
Deviance information criteria 147.018
Based on 13 RCTs with 1108 patients: 11 two-arm trials and two three-arm trials
Significant odds ratios are in italics
For absolute rates for events used for calculation of risk difference, please see Appendix 6
OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF
leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
CYC + AZA CYC with AZA, MMF-AZA MMF followed by AZA
Merged doses for PRED and CYC and comparing only between treatments. We did not lose any study, but it is a limitation of this analysis
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and CYC HD (Table 5). The quality of evidence was
rated as moderate (downgraded for imprecision). Abso-
lute event rates ranged from 7 to 30 % and are shown in
more detail in an additional file (see Additional file 6).
Sensitivity analyses limited to partial or complete renal
remission only
An additional file shows in detail the odds ratios for compari-
sons of immunosuppressive drugs and corticosteroids in lupus
nephritis for partial/complete remission, a sensitivity analysis
(renal response excluded from the composite outcome; see
Additional file 7). Results were similar to the main analyses,
with minor exceptions. Thus, most observations from the
main analysis were confirmed in this sensitivity analysis.
Rankograms and staircase diagrams
Figure 2 shows the Rankograms for various treatments
for the outcomes of interest. Among the top ranked
were CSA for renal remission/response, prednisone for
renal relapse/flare, CYC for ovarian failure/amenorrhea
and CYC for bone marrow toxicity (Fig. 3). An add-
itional file shows in detail comparisons of various treat-
ments to each other for each outcome, another way to
visualize the key comparisons between treatments (see
Additional file 8).
Discussion
In this systematic review and NMA of outcomes in pa-
tients with lupus nephritis, we made several important
observations. Results of this study are of great value to
both medical and patient communities, given the grow-
ing and renewed focus on patient-centered education
and outcomes. We directly compared benefits and risks
of medications that are used to treat SLE nephritis. The
information presented here served as the foundation for
a decision-aid tool that can be easily understood that is
being tested in a randomized trial, currently underway.
Given the novel NMA methodology and our ability to
perform indirect comparisons using the NMA, several of
our findings are new and merit further discussion.
We noted differences between immunosuppressive
drugs regarding renal remission/response. Interestingly,
high-dose CYC was significantly less effective than MMF
in leading to renal remission/response with a relative
risk of 0.65 and an odds ratio of 0.40. This is an interest-
ing finding and is consistent with the trial data from
Ginzler et al. that found that MMF was superior to IV
CYC in inducing complete renal remission [37].
We also found that CYC LD (which includes EURO-
lupus regimen) was inferior to MMF, CSA and CYC
standard dose for renal remission/response. We realize
that not all trials are same; however, the superiority of
these commonly used immunosuppressive drugs to CYC
LD is worth some discussion. This benefit of using
low-dose CYC must be weighed against the potential
harms of using MMF, CSA or CYC standard dose in a
patient with lupus nephritis. Several other differences
we noted might be of interest to clinicians and pa-
tients when making treatment decisions for lupus
nephritis.
Table 4 Comparison of all lupus nephritis treatments for fertility issues (amenorrhea or ovarian failure)
Treatment Reference OR (95 % CrI) RR (95 % CrI) RD % (95 % Crl)
CYC PRED 3.81 (1.26, 14.31) 2.64 (1.18, 7.51) 0.25 (0.04, 0.47)
MMF 0.48 (0.09, 3.04) 0.52 (0.11, 2.58) −0.07 (−0.23, 0.13)
AZA 2.74 (0.26, 28.27) 2.12 (0.30, 8.18) 0.17 (−0.15, 0.65)
CYC LD 9.06 (0.63, 121.50) 3.79 (0.68, 11.71) 0.45 (−0.06, 0.81)
MMF CYC 0.13 (0.03, 0.41) 0.20 (0.05, 0.56) −0.31 (−0.47, −0.16)
AZA 0.69 (0.09, 5.08) 0.79 (0.14, 1.95) −0.08 (−0.37, 0.36)
CYC LD 2.23 (0.23, 23.20) 1.46 (0.34, 2.71) 0.19 (−0.27, 0.55)
AZA MMF 5.25 (0.78, 54.39) 3.68 (0.81, 19.08) 0.22 (−0.02, 0.68)
CYC LD 16.35 (1.97, 247.70) 6.49 (1.72, 30.95) 0.50 (0.06, 0.87)
CYC LD AZA 3.20 (0.55, 21.24) 1.69 (0.68, 6.12) 0.22 (−0.11, 0.60)
Random-effects model Residual deviance 15.93 vs. 17 data points
Deviance information criteria 72.233
Fixed-effects model Residual deviance 16.16 vs. 17 data points
Deviance information criteria 72.069
Based on eight RCTs with 839 patients: seven two-arm trials and one three-arm trial
Significant odds ratios are in italics
For absolute rates for events used for calculation of risk difference, please see Appendix 6
OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, HD high dose, LD low dose; when not specified, it indicates standard dose, CYC cyclophosphamide,
MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients
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We confirmed that immunosuppressive drugs were
more effective than corticosteroids alone (most often
prednisone or prednisolone) for renal remission/response
by two to four times, that is, CYC, MMF, CSA, and tacro-
limus led to renal remission significantly more often than
corticosteroids alone. The lower risk of renal relapse or
flare with MMF and CYC compared to corticosteroids
alone is also supportive of this finding and not surpris-
ing. Other immunosuppressives (AZA, CSA, CYC-
AZA, MMF-AZA) also seemed to be possibly more
effective than corticosteroids alone for preventing renal
relapse/flare, but did not reach significance.
Significant differences were found in the risk of amenor-
rhea/ovarian failure (fertility issues). These are important
findings, since a disproportionate number of young
women are affected by lupus. An increased risk of amen-
orrhea/ovarian failure was seen with CYC compared to
MMF and PRED, which confirms a long-known clinical
observation, but now provides estimates of the compara-
tive risk. Ovarian failure is an important discussion point
during lupus treatment decision-making in young women,
especially when the use of CYC is considered.
We found that CYC SD, CYC LD, CYC HD, and AZA
had two to five times higher risk of cytopenia than MMF.
Our comprehensive NMA provided a robust treatment esti-
mates for these comparisons that can be shared with patients
in a more understandable format at the time of treatment
decision-making for lupus nephritis in regular clinical care.
Our study has several limitations. Meta-analyses are
observational studies and therefore can have limitations
of any observational study. Heterogeneity is an issue
with all meta-analyses, including NMA. We assessed for
clinical heterogeneity of studies prior to conducting the
analyses, with the help of two clinicians (including a
rheumatologist and a lupus expert) who assessed for sys-
tematic differences between study populations and dis-
ease stage by medications regimens. We noted some
clinical heterogeneity between trials, but did not find
major systematic differences by the type of medication
used. We acknowledge that no two clinical trials are
alike. This applies to our NMA as well, and therefore,
the results should be interpreted with some caution.
Another study limitation may be that we searched two
databases.
Table 5 Comparison of all lupus nephritis treatments for bone marrow toxicity (cytopenia including leucopenia)
Treatment Reference OR (95 % CrI) RR (95 % CrI) RD % (95 % Crl)
CYC SD MMF 2.16 (1.14, 4.03) 1.99 (1.13, 3.37) 0.07 (0.01, 0.16)
AZA SD 2.42 (1.01, 7.07) 2.19 (1.01, 5.06) 0.09 (0.00, 0.27)
CYC LD 5.31 (1.26, 24.65) 4.03 (1.23, 10.11) 0.22 (0.02, 0.56)
CYC HD 5.36 (1.95, 18.08) 4.06 (1.81, 8.96) 0.22 (0.07, 0.48)
RTX +MMF SD 3.50 (0.61, 23.14) 2.95 (0.63, 9.43) 0.14 (−0.03, 0.56)
AZA SD CYC SD 1.11 (0.39, 4.03) 1.09 (0.44, 3.07) 0.01 (−0.11, 0.22)
CYC LD 2.45 (0.51, 13.07) 2.01 (0.56, 5.91) 0.15 (−0.08, 0.50)
CYC HD 2.47 (0.77, 9.99) 2.03 (0.80, 5.38) 0.15 (−0.04, 0.43)
RTX +MMF SD 1.63 (0.26, 11.77) 1.49 (0.30, 5.31) 0.07 (−0.13, 0.49)
CYC LD AZA SD 2.16 (0.42, 10.83) 1.80 (0.49, 5.39) 0.13 (−0.12, 0.47)
CYC HD 2.20 (0.56, 8.96) 1.83 (0.65, 5.16) 0.13 (−0.10, 0.40)
RTX +MMF SD 1.43 (0.18, 11.42) 1.33 (0.23, 5.33) 0.05 (−0.21, 0.48)
CYC HD CYC LD 1.01 (0.29, 3.75) 1.01 (0.46, 2.74) 0.00 (−0.28, 0.24)
RTX +MMF SD 0.66 (0.06, 7.15) 0.74 (0.12, 3.78) −0.07 (−0.48, 0.40)
RTX +MMF SD CYC HD 0.65 (0.08, 5.36) 0.73 (0.13, 2.81) −0.08 (−0.41, 0.37)
Random-effects model Residual deviance 31.43 vs. 33 data points
Deviance information criteria 165.076
Fixed-effects model Residual deviance 38.78 vs. 33 data points
Deviance information criteria 167.984
Based on 16 RCTs with 2257 patients: 15 two-arm trials and one three-arm trial
Significant odds ratios are in italics
For absolute rates for events used for calculation of risk difference, please see Appendix 6
OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, HD high dose, LD low dose; when not specified, it indicates standard dose, CYC cyclophosphamide,
MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
MMF-AZA, MMF followed by AZA
RTX +MMF, RTX combined with MMF
Estimates for LEF HD were obtained from data from only one study and were therefore imprecise
The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients
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The NMA incorporates both direct and indirect com-
parisons. As can be seen from the network diagrams for
these analyses, for some outcomes assessed in this study,
direct comparisons were fewer, which indicates that
most evidence came from indirect comparisons; addition
of data from direct comparator trials in future NMA
would increase the confidence in these findings. Due to
multiple NMA comparisons performed, some findings
may be resulting from chance. However, we think that
type II error, i.e., missing important differences due to
small sample size, is a bigger concern, since most in-
cluded trials for this rare condition, were of small size.
For comparisons with large relative effects (odds or risk
ratios), one should keep in mind the underlying rates,
which varied between outcomes and were very low for
some composite outcomes. In these cases, the absolute
difference between treatments is still small, even though
relative effect may be five or ten times, or 0.05 times.
Comparisons with wider confidence intervals must be
interpreted with caution, since these indicate small study
numbers, or a lower confidence in the certainty of the
estimate. It is possible (and even likely sometimes) that













































































Fig. 3 Rankograms for composite study outcomes in lupus nephritis, renal remission or renal response (a), renal relapse or renal flare (b), fertility
issues (c), and bone marrow toxicity (d). Legend: This two-dimensional plot show on the x-axis (horizontal) the possible ranks of the treatment
from best to the last ranks and on the y-axis (vertical) the probability of each of the treatments to assume those possible ranks for each outcome.
For example, for renal relapse/flare (an undesired outcome), the highest probability was evident with corticosteroids alone, followed by
MMF-AZA, followed by AZA and others
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Conclusions
This systematic review and NMA provides the most
current, comprehensive comparison of immunosuppres-
sive medications and corticosteroids used to treat lupus
nephritis. These findings must be interpreted consider-
ing between study heterogeneity. This comparative ef-
fectiveness research provides estimates of key benefits
and harms that would be of interest to both physicians
and their patients. The state-of-the-art methodology
used here should be duplicated for other diseases where
physicians and patients will benefit from comparisons of
commonly used treatments.
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